Re: Sarcopenia is a Poor Prognostic Factor of Castration-Resistant Prostate Cancer Treated with Docetaxel Therapy

被引：0
|
作者：
Griebling, Tomas L.
机构：
来源：
JOURNAL OF UROLOGY | 2020年 / 203卷 / 01期
关键词：
D O I：
10.1097/01.JU.0000604840.21681.4b
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：10 / 11
页数：2
相关论文
共 50 条
  • [21] Prognostic impact of prior local therapy in castration-resistant prostate cancer
    Koura, Mikifumi
    Shiota, Masaki
    Ueda, Shohei
    Matsumoto, Takashi
    Kobayashi, Satoshi
    Monji, Keisuke
    Kashiwagi, Eiji
    Takeuchi, Ario
    Inokuchi, Junichi
    Shiga, Ken-ichiro
    Yokomizo, Akira
    Eto, Masatoshi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (07) : 1142 - 1148
  • [22] Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel
    Ryan, Charles J.
    Dutta, Sandipan
    Kelly, William K.
    Middleberg, Rob
    Russell, Carly
    Morris, Michael J.
    Taplin, Mary-Ellen
    Halabi, Susan
    CLINICAL GENITOURINARY CANCER, 2020, 18 (03) : 222 - +
  • [23] Phospholipids as Indicators of Docetaxel-Resistant Castration-Resistant Prostate Cancer
    Ingram, Lishann M.
    Mansoura, Maryam
    Cummings, Brian S.
    FASEB JOURNAL, 2019, 33
  • [24] TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL IN PORTUGAL
    Silva Miguel, L.
    Paquete, A. T.
    Guerreiro, R.
    Fiorentino, F.
    Costa, J.
    Borges, M.
    VALUE IN HEALTH, 2018, 21 : S71 - S71
  • [25] Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
    Mahon, K. L.
    Lin, H-M
    Castillo, L.
    Lee, B. Y.
    Lee-Ng, M.
    Chatfield, M. D.
    Chiam, K.
    Breit, S. N.
    Brown, D. A.
    Molloy, M. P.
    Marx, G. M.
    Pavlakis, N.
    Boyer, M. J.
    Stockler, M. R.
    Daly, R. J.
    Henshall, S. M.
    Horvath, G.
    BRITISH JOURNAL OF CANCER, 2015, 112 (08) : 1340 - 1348
  • [26] Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
    K L Mahon
    H-M Lin
    L Castillo
    B Y Lee
    M Lee-Ng
    M D Chatfield
    K Chiam
    S N Breit
    D A Brown
    M P Molloy
    G M Marx
    N Pavlakis
    M J Boyer
    M R Stockler
    R J Daly
    S M Henshall
    L G Horvath
    British Journal of Cancer, 2015, 112 : 1340 - 1348
  • [27] Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
    Marin-Aguilera, Mercedes
    Codony-Servat, Jordi
    Kalko, Susana G.
    Fernandez, Pedro L.
    Bermudo, Raquel
    Buxo, Elvira
    Jose Ribal, Maria
    Gascon, Pedro
    Mellado, Begona
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (02) : 329 - 339
  • [28] Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel
    Belderbos, Bodine P. S.
    de Wit, Ronald
    Oomen-de Hoop, Esther
    Nieuweboer, Annemieke
    Hamberg, Paul
    van Alphen, Robbert J.
    Bergman, Andre
    van der Meer, Nelly
    Bins, Sander
    Mathijssen, Ron H. J.
    van Soest, Robert J.
    ONCOTARGET, 2017, 8 (63) : 106468 - 106474
  • [29] Retreatment with docetaxel in metastatic castration-resistant prostate cancer (CRPC).
    Gernone, A.
    Pagliarulo, A.
    Pagliarulo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] γ-Klotho is correlated with resistance to docetaxel in castration-resistant prostate cancer
    Onishi, Kenta
    Miyake, Makito
    Hori, Shunta
    Onishi, Sayuri
    Iida, Kota
    Morizawa, Yosuke
    Tatsumi, Yoshihiro
    Nakai, Yasushi
    Tanaka, Nobumichi
    Fujimoto, Kiyohide
    ONCOLOGY LETTERS, 2020, 19 (03) : 2306 - 2316
12345